Finance

Beta
Lists
RHHBY:OTCMKTS
Roche Holdings AG Basel ADR Common Stock
$52.53
+0.33%
(+0.17) 1D
May 29, 3:22:19 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RHHBY...
Open
$52.84
High
$52.97
Low
$52.36
Mkt. cap
340.28B
Avg. vol.
2.32M
Volume
601.07K
P/E ratio
20.54
52-wk high
$60.85
52-wk low
$37.51
EPS
$2.56
Beta
0.46
Shares outstanding
5.62B
No. of employees
113K
Open
$52.84
High
$52.97
Low
$52.36
Mkt. cap
340.28B
Avg. vol.
2.32M
Volume
601.07K
P/E ratio
20.54
52-wk high
$60.85
52-wk low
$37.51
EPS
$2.56
Beta
0.46
Shares outstanding
5.62B
No. of employees
113K
News stories
From sources across the web
Profile
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76. The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights, with Swiss pharma firm Novartis owning a further third of its shares until 2021. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia
About Roche Holdings AG Basel ADR Common Stock
CEOThomas Schinecker
Employees113K
FoundedOct 1, 1896
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websiteroche.com
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
15.92B
15.92B
15.75B
15.75B
Cost of goods sold
3.87B
3.87B
4.21B
4.21B
Cost of revenue
3.87B
3.87B
4.21B
4.21B
Research and development expenses
3.11B
3.11B
3.15B
3.15B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.29B
3.29B
3.59B
3.59B
Operating expense
6.30B
6.30B
6.82B
6.82B
Total operating expenses
10.17B
10.17B
11.03B
11.03B
Operating income
5.75B
5.75B
4.72B
4.72B
Other non operating income
4.00M
4.00M
-1.50M
-1.50M
EBT including unusual items
4.79B
4.79B
3.69B
3.69B
EBT excluding unusual items
5.46B
5.46B
4.37B
4.37B
Income tax expense
878.00M
878.00M
709.00M
709.00M
Effective tax rate
18.31%
18.31%
19.20%
19.20%
Other operating expenses
-110.50M
-110.50M
77.50M
77.50M
Net income
3.70B
3.70B
2.74B
2.74B
Net profit margin
23.27%
23.27%
17.36%
17.36%
Earnings per share
-
-
-
-
Interest and investment income
56.50M
56.50M
45.00M
45.00M
Interest expense
-304.00M
-304.00M
-289.50M
-289.50M
Net interest expenses
-247.50M
-247.50M
-244.50M
-244.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
6.53B
6.53B
5.50B
5.50B
Gain or loss from assets sale
-
-
-21.50M
-21.50M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer